CD19 is also expressed on normal B cells, and despite the on-target, off-tumor toxicity of B-cell aplasia with hypogammaglobinemia, patients do well in the short term, and those with recurrent infections can receive therapy with intravenous immunoglobulin (IVIG) supplementation. Here, CD19 is linked to neoplasm.